Molecular phenotypes of human parvovirus B19 in patients with myocarditis

Figure 6 Distribution of B19V-coinfection with cardiotropic viruses. A: In endomyocardial biopsies determined by virus-specific nPCR; B: Frequency of B19V-coinfection with cardiotropic viruses; C: qPCR of B19V loads in B19V mono- and co-infection; D: Distribution of B19V-genotype 1 and 2 in B19V mono- and co-infection in endomyocardial biopsies (EMBs); E: B19V loads of B19V mono- and co-infection in EMBs of patients with iCMP and DCM. One-way Anova was highly significant (P < 0.0001); F: B19V loads of B19V mono- and co-infection with cardiotropic viruses. One-way Anova was highly significant (P = 0.0091); G: Luciferase reporter assay to determine transactivation capacity of the HHV6-U94 transactivator on the B19V P6-promoter activity. P < 0.05 is statistically significant (two-tailed T-test). HHV6: Human herpesvirus 6; EV: Enterovirus; HCMV: Human cytomegalovirus; EBV: Epstein-Barr virus; DCM: Dilated cardiomyopathy; iCMP: Inflammatory cardiomyopathy; qPCR: Quantitative real-time polymerase chain reaction.